dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2015-12-07T15:35:53Z
dc.date.available2015-12-07T15:35:53Z
dc.date.created2015-12-07T15:35:53Z
dc.date.issued2015
dc.identifierCurrent Medicinal Chemistry, v. 22, n. 27, p. 3133-3161, 2015.
dc.identifier1875-533X
dc.identifierhttp://hdl.handle.net/11449/131461
dc.identifier10.2174/0929867322666150818103836#sthash.EOREFJmy.dpuf
dc.identifier9734333607975413
dc.identifier26282941
dc.identifier0000-0003-4141-0455
dc.description.abstractTuberculosis (TB) is an infectious disease caused by bacterium of the Mycobacterium genus, mainly by Mycobacterium tuberculosis (MTB). The World Health Organization aims to substantially reduce the number of cases in the coming years; however, the increased number of multidrug-resistant (MDR) and extremely drug-resistant (XDR) forms of the bacterium and the lack of treatment for latent tuberculosis are challenges to be overcome. In this review, we have identified the most potent compounds described in the literature during recent years with MIC values < 7 µM, low toxicity and a high selective index. In addition, emerging targets in MTB are presented to provide new perspectives for the discovery of new antitubercular drugs. This review aims to summarize the current advances in and promote insights into antitubercular drug discovery.
dc.languageeng
dc.publisherBentham Science Publishers
dc.relationCurrent Medicinal Chemistry
dc.rightsAcesso restrito
dc.sourcePubMed
dc.subjectAntitubercular drugs
dc.subjectDrug discovery
dc.subjectMycobacterium tuberculosis
dc.subjectResistant tuberculosis
dc.subjectTuberculosis
dc.subjectTuberculosis targets
dc.titleCurrent advances in antitubercular drug discovery: potent prototypes and new targets
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución